12 active not recruiting, 12 completed, 6 recruiting, 2 not yet recruiting. 35 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 35 | Active not recruiting 12, Completed 12, Recruiting 6, Not yet recruiting 2, Terminated 2, Unknown 1 |
| Phase 2 | 3 | Active not recruiting 2, Not yet recruiting 1 |
Follow Abiraterone Acetate: new trials by email Literature Review of Abiraterone Acetate trials Research Report on Abiraterone Acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 670 | 2026-05-04 | 2026-10-19 |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Xaluritamig, Abiraterone acetate, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | Amgen | 750 | 2025-11-28 | 2026-10-20 |
| REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial Abiraterone Acetate, Bicalutamide, Biospecimen Collection - Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Recruiting | Emory University | 72 | 2025-01-31 | 2026-02-24 |
| Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT, Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT - Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer) | Phase 3 | Not yet recruiting | Ding-Wei Ye | 400 | 2025-01-30 | 2025-01-10 |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) Opevesostat, Abiraterone acetate, Enzalutamide - Prostate Cancer Metastatic | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1310 | 2023-12-31 | 2026-10-06 |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) Opevesostat, Dexamethasone, Fludrocortisone acetate - Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1314 | 2023-12-18 | 2026-10-20 |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents Saruparib, Placebo, Abiraterone Acetate - Metastatic Castration-Sensitive Prostate Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1898 | 2023-11-21 | 2026-07-29 |
| Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) olaparib, abiraterone acetate - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Active not recruiting | AstraZeneca | 110 | 2021-06-24 | 2026-08-28 |
| Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent VERU-111, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | Phase 3 | Terminated | Veru Inc. | 105 | 2021-06-24 | 2024-02-05 |
| TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer TAVT-45, Zytiga, Prednisone - Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | Phase 3 | Completed | Tavanta Therapeutics | 107 | 2021-05-05 | 2024-01-16 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 496 | 2021-03-18 | 2024-12-31 |
| Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC Cabozantinib, Atezolizumab, Abiraterone Acetate - Metastatic Prostate Cancer, Prostate Adenocarcinoma | Phase 3 | Active not recruiting | Exelixis | 575 | 2020-10-19 | 2025-12-18 |
| A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC) Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone - Prostatic Neoplasms | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 696 | 2020-09-23 | 2026-09-28 |
| Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency Capivasertib, Placebo, Abiraterone Acetate - Hormone-Sensitive Prostate Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1012 | 2020-07-13 | 2026-09-10 |
| Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT Prednisone, Apalutamide, Abiraterone Acetate - Prostate Cancer | Phase 3 | Terminated | Dana-Farber Cancer Institute | 12 | 2020-04-20 | 2024-09-19 |
| Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide. Docetaxel, Abiraterone Acetate or Enzalutamide - Metastatic Castration-resistent Prostate Cancer | Phase 3 | Unknown | National Cancer Institute, Naples | 18 | 2019-09-01 | 2023-03-24 |
| Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) Pembrolizumab, Olaparib, Abiraterone acetate - Prostatic Neoplasms | Phase 3 | Completed | Merck Sharp & Dohme LLC | 793 | 2019-05-02 | 2025-05-18 |
| ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer Enzalutamide Oral Capsule, Abiraterone Oral Tablet, Carboplatin - Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 3 | Recruiting | Karolinska Institutet | 750 | 2019-02-01 | 2025-04-09 |
| A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer Niraparib, Abiraterone Acetate, Prednisone - Castration-Resistant Prostatic Cancer | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 765 | 2019-01-25 | 2026-09-25 |
Showing 20 of 35. Sign in to see all of them.
Prostatic Neoplasms (22) · Neoplasms (2) · Prostatic Neoplasms, Castration-Resistant (2) · Breast Neoplasms (1) · Neoplasm Metastasis (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Janssen Research & Development, LLC (7) · AstraZeneca (6) · Merck Sharp & Dohme LLC (3) · Alliance Foundation Trials, LLC. (1) · Amgen (1) · Aragon Pharmaceuticals, Inc. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Cougar Biotechnology, Inc. (1) · Dana-Farber Cancer Institute (1) · Ding-Wei Ye (1) · ECOG-ACRIN Cancer Research Group (1) · Eli Lilly and Company (1) · Emory University (1) · Exelixis (1) · Jiangsu HengRui Medicine Co., Ltd. (1)
United States (24) · Spain (22) · France (21) · United Kingdom (21) · Australia (20) · Germany (19) · Belgium (17) · Canada (17) · South Korea (16) · China (15) · Netherlands (15) · Italy (14) · Brazil (13) · Japan (13) · Taiwan (12)
Fred Saad, MD (2) · Noel Clarke, M.D. (2) · Andreas Maetzel, MD, PhD (1) · Anthony D'Amico, MD, PhD (1) · Arun Azad, MD (1) · Ashkan Mortezavi, MD, PhD (1) · Clorinda Schettino, MD (1) · Cougar Biotechnology, Inc Clinical Trial (1) · Evanthia Evanthia Galanis, MD (1) · Francesco Perrone, MD, PhD (1)
PMID 25829400, PMID 26609008, PMID 41732008, PMID 42286315, PMID 18990168, PMID 21612468, PMID 22452894, PMID 22747660, PMID 22995653, PMID 23142059, PMID 23228172, PMID 23816964, PMID 23973186, PMID 24075621, PMID 24099659, PMID 24647231, PMID 24787968, PMID 25593303, PMID 25601341, PMID 25624432, PMID 25800753, PMID 25985882, PMID 26278649, PMID 26685010, PMID 26718929, PMID 26719232, PMID 27402060, PMID 28300506, PMID 28578607, PMID 28578639, PMID 28939004, PMID 29272162, PMID 29326030, PMID 29529169, PMID 30355464, PMID 30521063, PMID 30987939, PMID 31560068, PMID 31754962, PMID 32203306, PMID 32343890, PMID 32586393, PMID 32955174, PMID 32994091, PMID 33270906, PMID 33599706, PMID 34373138, PMID 34420037, PMID 34600602, PMID 34757812
2023 (8), 2016 (3), 2018 (2), 2004 (1), 2008 (1), 2014 (1), 2017 (1), P30CA138292 (1), U10CA180820 (1)